GB918754A - Improvements in or relating to corticotrophin preparations - Google Patents

Improvements in or relating to corticotrophin preparations

Info

Publication number
GB918754A
GB918754A GB2792859A GB2792859A GB918754A GB 918754 A GB918754 A GB 918754A GB 2792859 A GB2792859 A GB 2792859A GB 2792859 A GB2792859 A GB 2792859A GB 918754 A GB918754 A GB 918754A
Authority
GB
United Kingdom
Prior art keywords
corticotrophin
preparations
gelatine
zinc
tannic acid
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired
Application number
GB2792859A
Inventor
Robert Edward Thompson
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Armour and Co
Original Assignee
Armour and Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Armour and Co filed Critical Armour and Co
Priority to GB2792859A priority Critical patent/GB918754A/en
Publication of GB918754A publication Critical patent/GB918754A/en
Expired legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/33—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans derived from pro-opiomelanocortin, pro-enkephalin or pro-dynorphin
    • A61K38/35—Corticotropin [ACTH]

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)

Abstract

Prolonged action corticotrophin preparations comprise an aqueous suspension of a water-in-soluble zinc - corticotrophin - gelatine - tannate complex which is prepared by adding, in any order, aqueous solutions of a zinc salt, tannic acid and partially hydrolysed (e.g. by autoclaving in aqueous solution thereof) gelatine to an aqueous solution of corticotrophin. The preparations may contain from 20 to 500 USP subcutaneous units per ml. of corticotrophin and from 0.1 to 2.5 mg. of tannic acid, from 6 to 60 mg. of partially hydrolysed gelatine and at least 0.25 mg. of zinc per 100 units of corticotrophin. The pH of the preparations is desirably between 4 and 8 and is preferably about 5. The corticotrophin used is preferably derived from porcine or bovine pituitary and may be of high or low potency and may be present in the preparations both as the insoluble complex and in solution. If corticotrophin derived from bovine pituitary is used, the gelatine may be omitted and an insoluble zince - corticotrophin - tannate complex results. Optional ingredients mentioned are cysteine (stabilizer) and antibacterial agents e.g. methyl and propyl p-aminobenzoates and phenol. The preparations may be lyophilized e.g. by freeze-drying.
GB2792859A 1959-08-14 1959-08-14 Improvements in or relating to corticotrophin preparations Expired GB918754A (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
GB2792859A GB918754A (en) 1959-08-14 1959-08-14 Improvements in or relating to corticotrophin preparations

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GB2792859A GB918754A (en) 1959-08-14 1959-08-14 Improvements in or relating to corticotrophin preparations

Publications (1)

Publication Number Publication Date
GB918754A true GB918754A (en) 1963-02-20

Family

ID=10267542

Family Applications (1)

Application Number Title Priority Date Filing Date
GB2792859A Expired GB918754A (en) 1959-08-14 1959-08-14 Improvements in or relating to corticotrophin preparations

Country Status (1)

Country Link
GB (1) GB918754A (en)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1999004764A1 (en) * 1997-07-23 1999-02-04 Perio Products Ltd. Tannic acid-polymer compositions for controlled release of pharmaceutical agents, particularly in the oral cavity
CN112540171A (en) * 2020-12-04 2021-03-23 郑州标源生物科技有限公司 Adrenocorticotropic hormone quality control product and preparation method thereof

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1999004764A1 (en) * 1997-07-23 1999-02-04 Perio Products Ltd. Tannic acid-polymer compositions for controlled release of pharmaceutical agents, particularly in the oral cavity
CN112540171A (en) * 2020-12-04 2021-03-23 郑州标源生物科技有限公司 Adrenocorticotropic hormone quality control product and preparation method thereof
CN112540171B (en) * 2020-12-04 2023-12-22 郑州标源生物科技有限公司 Corticotropin quality control product and preparation method thereof

Similar Documents

Publication Publication Date Title
ANTONIADES et al. Studies on the state of insulin in blood:“free” insulin and insulin complexes in human sera and their in vitro biological properties
Shaar et al. Effect of vasoactive intestinal polypertide on prolactin release in vitro
NO940663L (en) Lyophilized polyalkylene oxide modified protein and polypeptide complexes with cyclodextrin
SE8101065L (en) ANTITROMBINBEREDNING
CA1115206A (en) Method for preparing urokinase injection
AR012849A1 (en) ANTIVIRICA PHARMACEUTICAL COMPOSITION.
GB1395090A (en) Stabilized hormone compositions
GB918754A (en) Improvements in or relating to corticotrophin preparations
KR860006982A (en) Method for preparing stable gamma interferon formulation
GB931016A (en) Amino acids concentrate and intravenous preparations thereof
NZ235153A (en) Stabilised alpha-interferon compositions
GB1038415A (en) Cosmetic preparations containing albumins
ES359547A1 (en) Lupus erythematosus skin test
GB1372812A (en) Cerebrospinal fluid control standard
GB941019A (en) Improvements in and relating to the stability of anti-haemophilic globulin (factor viii)
ES387885A1 (en) Pharmaceutical preparations comprising chondroitin sulphates a and c
DK0873134T3 (en) Prolonged release formulation comprising bovine growth hormone releasing factor
IE38514L (en) Insulin preparations.
GB845705A (en) Improvements in enhancing the potency of adrenocorticotrophin preparations
Pincus Qualitative tests on human enamel protein
ES2139881T3 (en) AQUEOUS DELAYED RELEASE FORMULATION.
GB807781A (en) Plasma fraction and standard plasma preparation and method of preparing same
Franklin et al. Biochemical studies with a new cytotoxic immunosuppressive agent, 3-acetyl-5-(4-fluorobenzylidene)-2, 5-dihydro-4-hydroxy-2-oxothiophen (ICI 47776)
US2909468A (en) Preparation of adrenocorticotrophin
GB698767A (en) Readily soluble dry preparations of swelling substances